NeoNovo: Holding subsidiary Daretuoyoudankang Injection obtained Drug Clinical Trial Approval Notification Letter

New notice from Sinoway, holding subsidiary Shiyao Group's Juishi Biopharmaceutical Co., Ltd. recently received the approved notification letter of drug clinical trial for Daratumumab Injection issued by the National Medical Products Administration. The clinical trial will be conducted soon. Daratumumab Injection is a recombinant fully human IgG1 monoclonal antibody targeting ADP-ribosyl cyclase, a biosimilar to the original drug Darzalex. It is suitable for the treatment of adult patients with multiple myeloma.